Galectin Therapeutics (GALT) AI Stock Analysis

• Market Cap: $206.33M
• Dividend Yield: N/A
• Average Volume (3M): 341.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.86
• Revenue Growth: N/A
• EPS Growth: 18.82%
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 64,479,210
• 10 Day Avg. Volume: 287,288
• 30 Day Avg. Volume: 341,945
• PEG Ratio: -0.63
• Price to Book (P/B): -0.78
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.92
• Enterprise Value/Market Cap: 1.18
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -11.04K
• Enterprise Value/Ebitda: -8.05
• 1Y Price Target: $11.00
• Price Target Upside: 92.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $4.00 ▼(-29.95% Downside)

The score is held down primarily by very weak financial performance (no meaningful revenue, heavy losses, negative equity, and continued cash burn with rising debt). Technicals also reflect a soft trend with negative momentum signals. Offsetting these, recent clinical/regulatory progress and insider financing support are positives but not enough to overcome the current financial risk profile.

Positive Factors

Clinical Trial Progress

Positive clinical trial results for Belapectin indicate potential for future product approval and commercialization, enhancing long-term growth prospects.

Partnership Opportunities

Potential partnerships can provide strategic resources and financial support, crucial for advancing R&D and reducing financial strain.

Innovative Drug Development

Targeting galectin proteins positions the company at the forefront of innovative treatments for fibrosis and cancer, offering a competitive edge in the biotech industry.

Negative Factors

Financial Instability

High leverage and negative equity indicate financial instability, which could hinder long-term operational sustainability and growth.

Zero Revenue Production

Lack of revenue generation underscores the risk of prolonged reliance on external funding, affecting financial health and investment attractiveness.

Increasing Financial Losses

Rising losses reflect increasing operational costs without revenue, posing a challenge to achieving profitability and financial stability.

Galectin Therapeutics Business Overview & Revenue Model

Company Description

Galectin Therapeutics Inc. is a biotechnology company focused on developing innovative therapies to improve the lives of patients with chronic liver diseases and cancer. The company operates in the biotechnology and pharmaceutical sectors, with a core emphasis on discovering and developing drugs targeting galectin proteins, which are critical in numerous disease processes. Galectin Therapeutics aims to leverage its proprietary technology to create novel treatments, primarily targeting fibrosis and cancer.

How the Company Makes Money

Galectin Therapeutics primarily makes money through research and development collaborations, licensing agreements, and milestone payments related to its drug candidates. The company partners with larger pharmaceutical firms to advance the development and commercialization of its therapies, receiving payments for achieving specific research and development milestones. Additionally, Galectin Therapeutics may earn revenue through licensing its proprietary technology and intellectual property to other companies, which can include upfront payments, royalties, and other financial incentives contingent upon the successful commercialization of their drug candidates.

Galectin Therapeutics Financial Statement Overview

Summary

Galectin Therapeutics exhibits the financial profile of an early-stage biotechnology company with no revenue production and increasing financial losses. The balance sheet is strained, marked by high debt and negative equity, suggesting potential financial risk. Cash flow trends demonstrate reliance on external financing to sustain operations, typical for firms focused on R&D in the biotech sector. This financial position underscores the importance of successful future product development and commercialization.

Income Statement

Galectin Therapeutics has consistently reported zero revenue over the last several years, indicating a lack of commercialized products. The net income has been negative, with losses growing from $13.38 million in 2019 to $47.05 million in 2024. This trend reflects increasing operating costs without offsetting revenue, a common challenge for biotechnology firms in the R&D phase.

Balance Sheet

The company has negative stockholders' equity, which worsened from $45.60 million positive in 2019 to $103.07 million negative in 2024, indicating high leverage and financial instability. The total debt has increased significantly, while assets remain low, reflecting potential liquidity issues and reliance on debt financing.

Cash Flow

Operating cash flow has been negative, indicating cash burn typical for pre-revenue biotech firms. However, the company has managed to secure financing cash flow intermittently, indicating some success in raising funds to support operations. Despite this, free cash flow remains negative, highlighting ongoing financial challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-22.00K	-37.00K	-33.00K	-32.00K	-41.00K	-36.00K
EBITDA	-30.17M	-41.47M	-38.24M	-37.71M	-30.00M	-23.34M
Net Income	-37.30M	-47.05M	-41.07M	-38.78M	-30.53M	-23.46M
Balance Sheet
Total Assets	12.87M	17.50M	28.20M	21.29M	41.83M	29.60M
Cash, Cash Equivalents and Short-Term Investments	11.53M	15.12M	25.66M	18.59M	39.65M	27.14M
Total Debt	122.31M	106.25M	71.81M	39.87M	29.06M	44.00K
Total Liabilities	138.17M	120.56M	88.44M	53.48M	39.21M	5.41M
Stockholders Equity	-125.30M	-103.07M	-60.24M	-32.19M	2.62M	24.19M
Cash Flow
Free Cash Flow	-30.62M	-41.77M	-32.97M	-31.06M	-24.31M	-20.60M
Operating Cash Flow	-30.62M	-41.77M	-32.97M	-31.06M	-24.31M	-20.60M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	15.09M	31.23M	40.03M	10.00M	36.81M	263.00K

Galectin Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.71
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GALT, the sentiment is Negative. The current price of 5.71 is above the 20-day moving average (MA) of 4.69, above the 50-day MA of 5.26, and above the 200-day MA of 3.48, indicating a bearish trend. The MACD of -0.57 indicates Positive momentum. The RSI at 28.25 is Positive, neither overbought nor oversold. The STOCH value of 10.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GALT.

Galectin Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TECX	55 Neutral	$401.65M	-5.57	-32.21%	―	―	60.40%
JBIO	55 Neutral	$609.56M	-1.17	-50.23%	14.68%	―	89.16%
OMER	52 Neutral	$953.61M	-6.67	―	―	―	12.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VYGR	46 Neutral	$225.74M	-1.87	-46.09%	―	-80.88%	-388.61%
GALT	44 Neutral	$206.33M	-5.41	―	―	―	18.82%
TNYA	44 Neutral	$167.14M	-0.98	-96.44%	―	―	46.68%

Galectin Therapeutics Corporate Events

Galectin Advances Belapectin Program, Secures New Insider Financing

On December 19, 2025, Galectin Therapeutics reported that the U.S. Food and Drug Administration provided a written response to the company’s Type C meeting request on the development program for belapectin, leading the company to believe there is regulatory alignment on the proposed patient population for a future registration trial in MASH cirrhosis. The company plans a follow-up Type C meeting to finalize remaining trial design details and to present new biomarker data, viewing this interaction as a key step toward a pivotal Phase 3 study and an opportunity to integrate input from external key opinion leaders, which it sees as important for advancing belapectin’s clinical strategy. Separately on December 19, 2025, Galectin Therapeutics entered into a new unsecured, convertible line of credit of up to $10 million with its chairman, Richard E. Uihlein, and extended the maturity of all his existing convertible credit lines and notes to June 30, 2027, a move that, together with existing cash, is expected to fund operations through at least March 2027 and underscores continued insider financial support as the company progresses its late-stage liver disease program.

The most recent analyst rating on (GALT) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.

Galectin Therapeutics Holds 2025 Annual Stockholders Meeting

At the 2025 Annual Meeting of Stockholders on December 3, 2025, Galectin Therapeutics‘ stockholders elected the nominated directors and approved a non-binding advisory resolution on executive compensation. They also ratified Cherry Bekaert LLP as the independent registered public accounting firm for the year ending December 31, 2025. The board decided to conduct advisory votes on executive compensation every three years.

The most recent analyst rating on (GALT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.

Galectin Therapeutics Reveals Promising NAVIGATE Trial Results

On December 3, 2025, Galectin Therapeutics presented compelling results from its NAVIGATE trial at its Annual Meeting of Stockholders. The trial focused on belapectin’s efficacy in treating MASH cirrhosis and portal hypertension, showing significant benefits in reducing liver stiffness and varices compared to placebo. The company highlighted the trial’s adaptive design and the decision to unblind data in 2024, which led to extensive data analysis throughout 2025. Key findings included belapectin’s impact on fibrosis and inflammation markers, with no drug-related serious adverse events reported. The results reinforce belapectin’s potential to change the treatment landscape for patients with no FDA-approved therapy, and Galectin is anticipating FDA feedback and exploring strategic opportunities to maximize program value.

The most recent analyst rating on (GALT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.

Galectin Therapeutics Presents Promising NAVIGATE Trial Results

On November 10, 2025, Galectin Therapeutics announced the presentation of its NAVIGATE trial results at the AASLD 2025 Annual Meeting. The Phase 2b trial evaluated belapectin, a galectin-3 inhibitor, in patients with compensated MASH cirrhosis and portal hypertension. The results demonstrated belapectin’s potential as a disease-modifying therapy, showing significant antifibrotic effects and a reduction in the incidence of new varices compared to placebo. These findings suggest a promising therapeutic option for patients with limited treatment choices, and the company is focused on advancing regulatory discussions and strategic partnerships to further develop belapectin.

The most recent analyst rating on (GALT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.